CD274 and cancer: Several potential biomarkers, such as the expression of programmed death-ligand 1 (PD-L1)8, tumor mutation burden9, microsatellite instability10, somatic copy number alterations11, immune inflamed phenotype12, T cell repertoire clonality change13, and human leukocyte antigen (HLA) class I diversity14, have been reported to be associated with response to ICIs across various cancer types.